March 2023 in “Translational Andrology and Urology” This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.
December 2022 in “JAMA network open” This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.
15 citations
,
March 2020 in “Anais Brasileiros De Dermatologia” This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.
30 citations
,
January 2020 in “Fertility and Sterility” This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” In this study, 5-α reductase inhibitors were not significantly linked to increased rhabdomyolysis risk, but they may raise the risk of myopathy and myositis in men aged 66 and older.
18 citations
,
June 2017 in “Journal of the neurological sciences” In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.
10 citations
,
December 2008 in “Journal of Clinical Neuromuscular Disease” This report describes a case where a man developed reversible myalgia and significant hyperCKemia after long-term finasteride use for male frontal baldness, with symptoms resolving upon discontinuation.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.